2 recruiting, 2 unknown, 1 completed. 2 Phase 2, 1 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 2 |
| Not applicable | 1 | Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow paclitaxel plus carboplatin: new trials by email Literature Review of paclitaxel plus carboplatin trials Research Report on paclitaxel plus carboplatin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma IMA203, nivolumab plus relatlimab, lifileucel - Melanoma, Cutaneous Malignant | Phase 3 | Recruiting | Immatics US, Inc. | 360 | 2025-01-14 | 2026-08-18 |
| Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15) Paclitaxel plus carboplatin, radiotherapy - Esophageal Squamous Cell Carcinoma, Chemoradiotherapy | Not applicable | Recruiting | Fudan University | 320 | 2020-01-06 | 2021-11-02 |
| Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma etoposide plus carboplatin, Paclitaxel plus carboplatin - Pulmonary Large Cell Neuroendocrine Carcinoma | Phase 2 | Unknown | Shanghai Chest Hospital | 118 | 2016-12-01 | 2016-10-25 |
| Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1) feladilimab (GSK3359609), GSK3174998, Pembrolizumab - Neoplasms | Phase 1 | Completed | GlaxoSmithKline | 829 | 2016-06-23 | 2024-12-27 |
| Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer Paclitaxel plus carboplatin, Paclitaxel and epirubicin - Triple Negative Breast Cancer | Phase 2 | Unknown | Chinese Academy of Medical Sciences | 80 | 2008-01-01 | 2011-11-16 |
Esophageal Squamous Cell Carcinoma (1) · Melanoma, Cutaneous Malignant (1) · Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Chinese Academy of Medical Sciences (1) · Fudan University (1) · GlaxoSmithKline (1) · Immatics US, Inc. (1) · Shanghai Chest Hospital (1)
China (3) · Canada (2) · France (2) · Netherlands (2) · United States (2) · Australia (1) · Germany (1) · Italy (1) · Japan (1) · Spain (1) · United Kingdom (1)
Cedrik Britten, M.D. (1) · Kuaile Zhao, doctor (1) · Xiangpeng Zheng, doctor (1) · Zhen Zhou, MD (1)
2016 (1)